Summary
Keywords
Introduction

Poulot A and Penin F. The HCV life cycle. Available from: http://hcvlifecycle.univ-lyon1.fr.
![]() |
Challenges in basic research on HCV
![]() |
Taxonomy
Model systems
HCV particle
HCV entry
HCV RNA
Structural biology
HCV RNA replication
Viral assembly and release
Drug discovery
Lessons from hepatitis A, B and E viruses
Immunology of viral hepatitis C
Challenges for translational and clinical hepatitis C research
Resistance-associated variants
Chimeric viruses
Renal insufficiency
- Roth D.
- Nelson D.R.
- Bruchfeld A.
- Liapakis A.
- Silva M.
- Monsour Jr, H.
- et al.
HCV genotype 3
Decompensated liver disease
Hepatocellular carcinoma
Shortening treatment duration
- Cornberg M.
- Manns M.
Screening for HCV
Treatment as prevention: Elimination of HCV in special patient populations
Patients on liver transplantation waiting list
Extrahepatic manifestations
HCV and lymphoproliferative disorders
Access to HCV therapy
Challenges in vaccine development for HCV
Conclusion

Conflict of interest
Acknowledgments
References
- The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection.Nat Rev Microbiol. 2013; 11: 482-496
- Novel therapies for hepatitis C – one pill fits all?.Nat Rev Drug Discovery. 2013; 12: 595-610
- From non-A, non-B hepatitis to hepatitis C virus cure.J Hepatol. 2015; 62: S87-S99
- Understanding the hepatitis C virus life cycle paves the way for highly effective therapies.Nat Med. 2013; 19: 837-849
Poulot A and Penin F. The HCV life cycle. Available from: http://hcvlifecycle.univ-lyon1.fr.
- Replication of hepatitis C virus.Nat Rev Microbiol. 2007; 5: 453-463
Bartenschlager R, editor. Hepatitis C virus: from molecular virology to antiviral therapy. Curr Top Microbiol Immunol. Springer; 2013.
- The Zika Challenge.N Engl J Med. 2016; 374: 1801-1803
- What’s next for hepatitis C virus research?.Hepatology. 2016; 63: 1408-1410
- Detection of zoonotic pathogens and characterization of novel viruses carried by commensal Rattus norvegicus in New York City.MBio. 2014; 5: e01933-e01944
- Surveying the global virome: identification and characterization of HCV-related animal hepaciviruses.Antiviral Res. 2015; 115: 83-93
- Highly divergent hepaciviruses from African cattle.J Virol. 2015; 89: 5876-5882
- Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line.Science. 1999; 285: 110-113
- Production of infectious hepatitis C virus in tissue culture from a cloned viral genome.Nat Med. 2005; 11: 791-796
- Animal models for hepatitis C.Curr Top Microbiol Immunol. 2013; 369: 49-86
- Cell culture systems for hepatitis C virus.Curr Top Microbiol Immunol. 2013; 369: 17-48
- Regulation of the hepatitis C virus RNA replicase by endogenous lipid peroxidation.Nat Med. 2014; 20: 927-935
- SEC14L2 enables pan-genotype HCV replication in cell culture.Nature. 2015; 524: 471-475
- Assembly of infectious hepatitis C virus particles.Trends Microbiol. 2011; 19: 95-103
- The ins and outs of hepatitis C virus entry and assembly.Nat Rev Microbiol. 2013; 11: 688-700
- Ultrastructural analysis of hepatitis C virus particles.Proc Natl Acad Sci U S A. 2013; 110: 9505-9510
- Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome.J Biol Chem. 2011; 286: 3018-3032
- Proteomics of HCV virions reveals an essential role for the nucleoporin Nup98 in virus morphogenesis.Proc Natl Acad Sci U S A. 2016; 113: 2484-2489
- Completion of the entire hepatitis C virus life cycle in genetically humanized mice.Nature. 2013; 501: 237-241
- Broadly neutralizing antibodies abrogate established hepatitis C virus infection.Sci Transl Med. 2014; 6: 254ra129
- Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody.Nat Biotechnol. 2015; 33: 549-554
- HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex.Cell Host Microbe. 2013; 13: 302-313
- Quantitative proteomics identifies serum response factor binding protein 1 as a host factor for hepatitis C virus entry.Cell Rep. 2015; 12: 864-878
- Hepatitis C virus utilizes VLDLR as a novel entry pathway.Proc Natl Acad Sci U S A. 2016; 113: 188-193
- Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA.Science. 1997; 277: 570-574
- Structural and mechanistic insights into hepatitis C viral translation initiation.Nat Rev Microbiol. 2007; 5: 29-38
- Hepatitis C virus RNA translation.Curr Top Microbiol Immunol. 2013; 369: 143-166
- A cis-acting replication element in the sequence encoding the NS5B RNA-dependent RNA polymerase is required for hepatitis C virus RNA replication.J Virol. 2004; 78: 1352-1366
- Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA.Science. 2005; 309: 1577-1581
- Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection.Science. 2010; 327: 198-201
- Treatment of HCV infection by targeting microRNA.N Engl J Med. 2013; 368: 1685-1694
- The coding region of the HCV genome contains a network of regulatory RNA structures.Mol Cell. 2016; 62: 111-120
- The yin and yang of hepatitis C: synthesis and decay of hepatitis C virus RNA.Nat Rev Microbiol. 2015; 13: 544-558
- Hepatitis C virus RNA functionally sequesters miR-122.Cell. 2015; 160: 1099-1110
- Hepatitis C virus proteins: from structure to function.Curr Top Microbiol Immunol. 2013; 369: 113-142
- Hepatitis C virus E2 envelope glycoprotein core structure.Science. 2013; 342: 1090-1094
- Unexpected structure for the N-terminal domain of hepatitis C virus envelope glycoprotein E1.Nat Commun. 2014; 5: 4874
- Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2.Nature. 2014; 509: 381-384
- HCV glycoprotein structures: what to expect from the unexpected.Curr Opin Virol. 2015; 12: 53-58
- Hepatitis C virus nonstructural protein 4B: a journey into unexplored territory.Rev Med Virol. 2010; 20: 117-129
- The lipid kinase phosphatidylinositol-4 kinase III alpha regulates the phosphorylation status of hepatitis C virus NS5A.PLoS Pathog. 2013; 9e1003359
- Hepatitis C virus RNA replication depends on specific cis- and trans-acting activities of viral nonstructural proteins.PLoS Pathog. 2015; 11e1004817
- NS5A domain 1 and polyprotein cleavage kinetics are critical for induction of double-membrane vesicles associated with hepatitis C virus replication.MBio. 2015; 6e00759
- Spatiotemporal analysis of hepatitis C virus infection.PLoS Pathog. 2015; 11e1004758
- Hepatitis C virus RNA replication.Curr Top Microbiol Immunol. 2013; 369: 167-198
- Hepatitis C virus RNA replication and assembly: living on the fat of the land.Cell Host Microbe. 2014; 16: 569-579
- Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.Nature. 2010; 465: 96-100
- Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA.Sci Rep. 2014; 4: 4765
- Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.Gastroenterology. 2014; 147: 1094-1095e25
- Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.Gastroenterology. 2014; 147: 453-462e7
- Asymmetric binding to NS5A by daclatasvir (BMS-790052) and analogs suggests two novel modes of HCV inhibition.J Med Chem. 2014; 57: 10031-10043
- A Refined Model of the HCV NS5A protein bound to daclatasvir explains drug-resistant mutations and activity against divergent genotypes.J Chem Inf Model. 2015; 55: 362-373
- Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A.Nature. 2015; 527: 245-248
- A pathogenic picornavirus acquires an envelope by hijacking cellular membranes.Nature. 2013; 496: 367-371
- Naked viruses that aren’t always naked: quasi-enveloped agents of acute hepatitis.Annu Rev Virol. 2014; 1: 539-560
- Reassessing immune control of hepatitis A virus.Curr Opin Virol. 2015; 11: 7-13
- Hepatitis E virus: time to change the textbooks.Dig Dis. 2016; 34: 308-316
- Update on hepatitis E virology: implications for clinical practice.J Hepatol. 2016; 65: 200-212
- Towards an HBV cure: state-of-the-art and unresolved questions–report of the ANRS workshop on HBV cure.Gut. 2015; 64: 1314-1326
- Present and future therapies of hepatitis B: From discovery to cure.Hepatology. 2015; 62: 1893-1908
- Global strategies are required to cure and eliminate HBV infection.Nat Rev Gastroenterol Hepatol. 2016; 13: 239-248
- Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins.Gastroenterology. 2010; 139: 965-974
- Hepatitis C virus reinfection and spontaneous clearance of reinfection–the InC3 study.J Infect Dis. 2015; 212: 1407-1419
- Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C.Gastroenterology. 1999; 117: 933-941
- Transient immunological control during acute hepatitis C virus infection: ex vivo analysis of helper T-cell responses.J Viral Hepat. 2006; 13: 708-714
- Adaptive immune responses in hepatitis C virus infection.Curr Top Microbiol Immunol. 2013; 369: 243-262
- Broadly directed virus-specific CD4+ T cell responses are primed during acute hepatitis C infection, but rapidly disappear from human blood with viral persistence.J Exp Med. 2012; 209: 61-75
- Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers.J Clin Invest. 2003; 112: 831-842
- Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes.J Immunol. 2005; 175: 3603-3613
- An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection.Hepatology. 2004; 40: 1062-1071
- Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection.Hepatology. 2003; 38: 1437-1448
- Galectin-9 and IL-21 mediate cross-regulation between Th17 and Treg cells during acute hepatitis C.PLoS Pathog. 2013; 9e1003422
- Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection.Hepatology. 2010; 51: 378-387
- Molecular and transcriptional basis of CD4(+) T cell dysfunction during chronic infection.Immunity. 2014; 40: 289-302
- The role of hepatitis C virus specific CD4+ T lymphocytes in acute and chronic hepatitis C.J Mol Med (Berl). 1996; 74: 583-588
- Tracking virus-specific CD4+ T cells during and after acute hepatitis C virus infection.PLoS One. 2007; 2e649
- Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression.J Virol. 2007; 81: 2545-2553
- Liver environment and HCV replication affect human T-cell phenotype and expression of inhibitory receptors.Gastroenterology. 2014; 146: 550-561
- Immune responses to HCV and other hepatitis viruses.Immunity. 2014; 40: 13-24
- HCV persistence and immune evasion in the absence of memory T cell help.Science. 2003; 302: 659-662
- Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction.J Virol. 2007; 81: 9249-9258
- PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion.J Virol. 2006; 80: 11398-11403
- Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1).Proc Natl Acad Sci U S A. 2013; 110: 15001-15006
- Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity.J Clin Invest. 2010; 120: 4546-4557
- Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells.Immunity. 2011; 35: 400-412
- All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.Lancet. 2014; 384: 1597-1605
Chu C, et al. Poster P006 (M13–767). APASL STC 2016; 2016; Taiwan.
Chu C, et al. Poster P007 (M14–491). APASL STC 2016; 2016; Taiwan.
- Daclatasvir plus sofosbuvir for treatment of HCV genotypes 1–4 in Hiv-Hcv coinfection: the ally-2 study.J Hepatol. 2015; 62: S263-S
- Virus resistance to direct-acting antiviral drugs in interferon-free regimens.Gastroenterology. 2016; 151: 70-86
- Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir- based regimens with ledipasvir/sofosbuvir for 24 weeks.J Hepatol. 2015; 62: S192-S
- Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis.N Engl J Med. 2015; 373: 2618-2628
- Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection.N Engl J Med. 2015; 373: 2599-2607
- Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection.N Engl J Med. 2015; 373: 2608-2617
- Resistance analysis in 1284 patients with genotype 1–6 HCV infection treated with sofosbuvir/velpatasvir in the phase 3 ASTRAL-1, ASTRAL-2, ASTRAL-3, and ASTRAL-4 studies.J Hepatol. 2016; 64: S399-S400
- Ombitasvir/paritaprevir/R, dasabuvir and sofosbuvir treatment of patients with HCV genotype 1 infection who failed a prior course of DAA therapy: the QUARTZ-1 Study.J Hepatol. 2016; 64: S767-S768
- High SVR rates with the combination of ABT-493 + ABT-530 for 8 weeks in non-cirrhotic patients with HCV genotype 1 or 2 infection.J Hepatol. 2016; 64: S768
- High efficacy of sofosbuvir/velpatasvir plus GS-9857 for 12 weeks in treatment-experienced genotype 1-6 HCV-infected patients, including those previously treated with direct-acting antivirals.J Hepatol. 2016; 64: S139-S140
- Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in low SVR rates in a real world cohort (German Hepatitis C Registry, DHC-R).J Hepatol. 2016; 64: S767
- Prevalence and clinical importance of hepatitis C virus genotype 2k/1b chimeras.J Hepatol. 2016; 64: S136
- Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease.Gastroenterology. 2016; 150: 1590-1598
- Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.Lancet. 2015; 386: 1537-1545
- EASL recommendations on treatment of hepatitis C 2015.J Hepatol. 2015; 63: 199-236
- Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.Hepatology. 2015; 62: 932-954
- Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease.Gastroenterology. 2015; 149: 649-659
- Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.Lancet Infect Dis. 2016; 16: 685-697
- Lamivudine for patients with chronic hepatitis B and advanced liver disease.N Engl J Med. 2004; 351: 1521-1531
- Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.J Hepatol. 2010; 53: 348-356
- Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.JAMA. 2012; 308: 2584-2593
- Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies.Ann Intern Med. 2013; 158: 329-337
- Unexpected early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy: a note of caution.J Hepatol. 2016; 65: 719-726
- High risk for hepatocellular carcinoma in cirrhotic patients with SVR following IFN-free DAA treatment within 1 year follow-up.J Hepatol. 2016; 64: S617-S618
- Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: The ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER, CO12 CIRVIR and CO23 CUPILT cohorts).J Hepatol. 2016; 65: 734-740
- Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.J Hepatol. 2016; 64: 1224-1231
- Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.Gastroenterology. 2011; 140 ([Quiz e12]): 840-849
- Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C.Gastroenterology. 2011; 140: 1990-1999
- Nonreversible MAIT cell-dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapy.Eur J Immunol. 2016; (in press)
- Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis.J Viral Hepat. 2016; 23: 496-505
- Safety and efficacy of short-duration treatment with Gs-9857 combined with sofosbuvir/Gs-5816 in treatment-naive and Daa-experienced genotype 1 patients with and without cirrhosis.J Hepatol. 2015; 62: S264-S
- C-SWIFT: MK-5172+MK-8742+sofosbuvir in treatment-naive patients with hepatitis C virus genotype 1 infection, with and without cirrhosis, for durations of 4, 6, or 8 weeks.Hepatology. 2014; 60: 1286A-1287A
- Six weeks of sofosbuvir/ledipasvir are sufficient to treat acute hepatitis C virus genotype 1 monoinfection: the HEPNET acute HCV IV study.J Hepatol. 2016; 64: S211
- Complete cure after three weeks of all-oral triple-direct acting antiviral (DAA) regimens in non-cirrhotic chronic hepatitis C genotype 1b Chinese subjects (SODAPI STUDY).Hepatology. 2015; 62: 1394A
- Hepatitis C: individualised medicine versus one pill fits all.Lancet Gastroenterol Hepatol. 2016; (in press)https://doi.org/10.1016/S2468-1253(16)30029-2
- The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm.J Viral Hepat. 2014; 21: 34-59
- Hepatitis C reinfection after sustained virological response.J Hepatol. 2016; 64: 1020-1026
Rockstroh J, Bhagani S, Hyland RH, Yun C, Zhang W, Brainard DM, et al. Ledipasvir/sofosbuvir for 6 weeks in HIV-infected patients with acute HCV infection. CROI 2016; Boston.
- Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.Gastroenterology. 2015; 148: 108-117
- Ledipasvir/sofosbuvir (LDV/SOF) for 12 or 24 weeks is safe and effective in kidney transplant recipients with chronic genotype 1 or 4 HCV infection.J Hepatol. 2016; 64: S183
- Extrahepatic morbidity and mortality of chronic hepatitis C.Gastroenterology. 2015; 149: 1345-1360
- Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population.JAMA. 2014; 312: 1927-1928
- Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2.Am J Gastroenterol. 2007; 102: 570-576
- Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial.J Hepatol. 2016; 65: 33-39
- Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study.Ann Rheum Dis. 2016; (in press)
- Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents.Hepatology. 2016; 63: 408-417
- Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection.N Engl J Med. 2002; 347: 89-94
- Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin’s lymphoma.J Hepatol. 2008; 49: 557-563
- Treatment as prevention and cure towards global eradication of hepatitis C virus.Trends Microbiol. 2013; 21: 625-633
- An epidemiologic update on hepatitis C infection in persons living with or at risk of HIV infection.J Infect Dis. 2013; 207: S1-S6
- Immunology of hepatitis B virus and hepatitis C virus infection.Nat Rev Immunol. 2005; 5: 215-229
- Hepatitis C virus: why do we need a vaccine to prevent a curable persistent infection?.Curr Opin Immunol. 2015; 35: 137-143
- Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection.J Exp Med. 2003; 197: 1645-1655
- T cell responses in hepatitis C: the good, the bad and the unconventional.Gut. 2012; 61: 1226-1234
- Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection.Gastroenterology. 2010; 138: 315-324
- A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees.Nat Med. 2006; 12: 190-197
- A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory.Sci Transl Med. 2014; 6: 261ra153
- The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments.BMC Med. 2015; 13: 198